PK assessments
BLOOD, SECONDARY
Systemic and local exposure to AG019 or its secreted proteins was assessed as a secondary endpoint. Blood and plasma samples were collected from all repeat-dose participants at screening, on day 12 and day 56 (last day of treatment), and at month 3 to evaluate the presence of AG019 in whole blood using plating and quantitative PCR (qPCR) and AG019-secreted hPINS and hIL-10 in plasma using ELISA. Faecal samples were collected from all repeat-dose participants in the high-dose monotherapy cohorts and all combination therapy cohorts at screening and on days 56, 58, 60, 62 and 64 to evaluate the presence of AG019 using qPCR.